Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is a major health problem worldwide, and most cases are
inoperable because of late presentation and underlying cirrhosis. It represents the fifth
most common tumor in the world and the third most frequent cause of mortality amongst
patients with cancer.
Due to the worldwide difficulties in finding liver for transplantation, hepatic resection
(HR) represents the main stay of curative treatment for patients with HCC. Transcatheter
arterial chemoembolization (TACE) is widely used as alternative treatments for unresectable
HCC or for patients not eligible to be operated on .
TACE also could be an adjuvant therapy for resectable HCC patients after hepatectomy, which
could prevent recurrence and improve long-term survival .